Simplex Trading
KYTX icon

Simplex Trading’s Kyverna Therapeutics KYTX Stock Holding History

Simplex Trading’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.35K Sell
600
-20,300
-97% -$180K ﹤0.01% 8129
2026
Q1 		$180K Buy
20,900
+900
+5% +$7.5K ﹤0.01% 4421
2025
Q4 		$188K Buy
+20,000
New +$148K ﹤0.01% 4293

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Simplex Trading's KYTX Position: Q2 2026 in Review

Simplex Trading sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 3,998 shares — an estimated $35.5K sold.

Simplex Trading first reported a position in KYTX in Q4 2024 and held it in 2 quarters. The position peaked at $34.5K in Q1 2026. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Simplex Trading reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 3,998 Kyverna Therapeutics shares in Q2 2026, an estimated $35.5K.
  • Simplex Trading first reported a position in Kyverna Therapeutics in Q4 2024 and held it in 2 quarters.
  • Simplex Trading's Kyverna Therapeutics position peaked at $34.5K in Q1 2026.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.